AR012684A1 - Acidos 6- y 7-amino-tetrahidroisoquinolinacarboxilicos sustituidos, procedimiento para su preparacion, su utilizacion en la preparacion de unmedicamento, medicamento que los contienen y procedimiento para su preparacion - Google Patents

Acidos 6- y 7-amino-tetrahidroisoquinolinacarboxilicos sustituidos, procedimiento para su preparacion, su utilizacion en la preparacion de unmedicamento, medicamento que los contienen y procedimiento para su preparacion

Info

Publication number
AR012684A1
AR012684A1 ARP980102174A ARP980102174A AR012684A1 AR 012684 A1 AR012684 A1 AR 012684A1 AR P980102174 A ARP980102174 A AR P980102174A AR P980102174 A ARP980102174 A AR P980102174A AR 012684 A1 AR012684 A1 AR 012684A1
Authority
AR
Argentina
Prior art keywords
alkyl
preparation
covalent bond
procedure
substituted
Prior art date
Application number
ARP980102174A
Other languages
English (en)
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of AR012684A1 publication Critical patent/AR012684A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Acidos 6- y 7-amino-tetrahidroisoquinolincarboxílicos sustituidos, que comprenden la formula (I) y/o una forma estereoisomera del compuesto de laformula (I) y/o una sal fisiologicamente compatible del compuesto de la formula (I),represe ntando en ella: R1 es: 1. fenilo, 2. fenilo, que estásustituido una vez o dos veces con: 2.1 alquilo C1-6, lineal, cíclico o ramificada, 2.2 -OH, 2.3 alquil C1-6-C(O)-O-, 2.4 alquil C1-6-O-, 2.5 alquilC1-6-O-alquil C1-4-O-, 2.6halogeno, 2.7 -CF3, 2.8 -CN, 2.9 -NO2, 2.10 HO-C(O)- , 2.11 alquil C1-6-O-C(O)-, 2.12 metilendioxo, 2.13 R5-(R6)N-C(O)-, en que R5 yR6 son iguales o diferentes y representan un átomo de hidrogeno o alquilo C1-6, o 2.14 R5-(R6)N-, en que R5 yR6 son iguales o diferentes yrepresentan un átomo de hidrogeno o alquilo C1-6; 3. un radical heteroaromático tomado entre el siguiente grupo 3.1 hasta 3.15, que está sin sustituir osustituido tal como se describe en 2.1 hasta 2.14: 3.1 pirrol, 3.2pirazol, 3.3 imida zol, 3.4 triazol, 3.5 tiofeno, 3.6 tiazol, 3.7 oxazol, 3.8 isoxazol,3.9 piridina, 3.10 pirimidina, 3.11 indol, 3.12 benzotiofeno, 3.13 bencimidazol, 3.14 benzoxazol o 3.15 benzotiazol; 4. -OH y significando A unenlacecovalente; 5. -O-R1 4 y significando A un enlace covalente, -CH=CH- o -C:::C- y en que R14 significa 1) alquilo C1-6, 2) cicloalquilo C3-6, 3)bencilo o 4) fenilo; 6. -COOH y significando A un enlace covalente, -CH=CH o -C:::C-; 7. alquiloC1-6; 8. cicloalquil C3- 6-O-alquilo C1-4; 9. halogeno ysignificando A un enlace covalente, -CH=CH- o -C:::C-, 10. -CN y significando A un enlace covalente, -CH=CH- o C:::C-; 11. -NO2 y significando A un enlacecovalente, -CH=CH- o C:::C-, o 12.-CF3, y representando R2: 1. HO(H)N- o 2. R7-O-, en que R7 significa 2.1 un átomo de hidrogeno, 2.2 alquilo C1-6,
ARP980102174A 1997-05-13 1998-05-11 Acidos 6- y 7-amino-tetrahidroisoquinolinacarboxilicos sustituidos, procedimiento para su preparacion, su utilizacion en la preparacion de unmedicamento, medicamento que los contienen y procedimiento para su preparacion AR012684A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19719817A DE19719817A1 (de) 1997-05-13 1997-05-13 Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren

Publications (1)

Publication Number Publication Date
AR012684A1 true AR012684A1 (es) 2000-11-08

Family

ID=7829213

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980102174A AR012684A1 (es) 1997-05-13 1998-05-11 Acidos 6- y 7-amino-tetrahidroisoquinolinacarboxilicos sustituidos, procedimiento para su preparacion, su utilizacion en la preparacion de unmedicamento, medicamento que los contienen y procedimiento para su preparacion

Country Status (18)

Country Link
US (1) US5962471A (es)
EP (1) EP0878467B1 (es)
JP (1) JP4384277B2 (es)
KR (1) KR19980086989A (es)
CN (1) CN1199045A (es)
AR (1) AR012684A1 (es)
AT (1) ATE207903T1 (es)
AU (1) AU731079B2 (es)
BR (1) BR9803694A (es)
CA (1) CA2237382A1 (es)
CZ (1) CZ145298A3 (es)
DE (2) DE19719817A1 (es)
DK (1) DK0878467T3 (es)
ES (1) ES2166577T3 (es)
HU (1) HUP9801072A3 (es)
PT (1) PT878467E (es)
RU (1) RU2212405C2 (es)
TR (1) TR199800841A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG116433A1 (en) * 1996-10-30 2005-11-28 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof.
FR2795730B1 (fr) * 1999-07-01 2001-08-31 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7521061B2 (en) * 1999-12-31 2009-04-21 Rutgers, The State University Of New Jersey Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix
AU784226B2 (en) * 1999-12-31 2006-02-23 Rutgers, The State University Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix
CN1366524A (zh) * 2000-04-07 2002-08-28 三星电子株式会社 磺胺衍生物作为基质金属蛋白酶抑制剂
GB0011409D0 (en) * 2000-05-11 2000-06-28 Smithkline Beecham Plc Novel compounds
WO2003016248A2 (en) * 2001-08-17 2003-02-27 Bristol-Myers Squibb Company Patent Department Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace)
US6608193B2 (en) 2001-12-21 2003-08-19 The Procter & Gamble Company Methods for synthesis of amino-tetrahydroisoquinoline ring compounds
US20020055637A1 (en) * 2001-12-21 2002-05-09 Song Liu Methods for synthesis of amino-tetrahydroisoquinoline-carboxylic acids
US6566524B2 (en) * 2001-12-21 2003-05-20 The Procter & Gamble Co. Methods for synthesis of amino-tetrahydroisoquinoline-sulfonamide hydroxamic acids
JP2006500350A (ja) * 2002-08-13 2006-01-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としてのイソキノリン誘導体
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
DE102005015040A1 (de) * 2005-03-31 2006-10-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
JP5098011B2 (ja) * 2006-11-20 2012-12-12 国立大学法人山口大学 創傷治癒促進剤
GB0706072D0 (en) * 2007-03-28 2007-05-09 Sterix Ltd Compound

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315935A (en) * 1980-04-14 1982-02-16 Smithkline Corporation N,N'-Bis[substituted-1,2,3,4-tetrahydroisoquinolinolyl]disulfonylimides and antiallergic compositions and method of use
US4344949A (en) * 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
US4681889A (en) * 1985-12-02 1987-07-21 Syntex (U.S.A.) Inc. Method for treating cardiovascular disease with calcium channel antagonists
US4613606A (en) * 1985-12-02 1986-09-23 Syntex (U.S.A.) Inc. Tetrahydroisoquinoline derivatives
JP2764262B2 (ja) * 1987-08-28 1998-06-11 持田製薬株式会社 ヒダントイン誘導体及びそれを有効成分とする医薬組成物
TW201303B (es) * 1990-07-05 1993-03-01 Hoffmann La Roche
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5714497A (en) * 1993-02-15 1998-02-03 Sanofi Compounds bearing sulphamoyl and amidino radicals, their preparation process and pharmaceutical compositions containing them
FR2701480B1 (fr) * 1993-02-15 1995-05-24 Sanofi Elf Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant.
AU2394795A (en) * 1994-04-28 1995-11-29 Du Pont Merck Pharmaceutical Company, The Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents
GB2303850B (en) * 1994-06-22 1998-06-10 British Biotech Pharm Metalloproteinase inhibitors
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US5861510A (en) * 1995-04-20 1999-01-19 Pfizer Inc Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
WO1997018194A1 (de) * 1995-11-13 1997-05-22 Hoechst Aktiengesellschaft CYCLISCHE UND HETEROCYCLISCHE N-SUBSTITUIERTE α-IMINOHYDROXAM- UND CARBONSÄUREN
GB9613547D0 (en) * 1996-06-27 1996-08-28 Pharmacia Spa Matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
DE59801919D1 (de) 2001-12-06
CN1199045A (zh) 1998-11-18
JPH10316662A (ja) 1998-12-02
KR19980086989A (ko) 1998-12-05
DE19719817A1 (de) 1998-11-19
US5962471A (en) 1999-10-05
CA2237382A1 (en) 1998-11-13
AU6593898A (en) 1998-11-19
EP0878467A1 (de) 1998-11-18
DK0878467T3 (da) 2002-02-18
HU9801072D0 (en) 1998-07-28
TR199800841A3 (tr) 1998-12-21
CZ145298A3 (cs) 1998-12-16
AU731079B2 (en) 2001-03-22
RU2212405C2 (ru) 2003-09-20
ATE207903T1 (de) 2001-11-15
TR199800841A2 (xx) 1998-12-21
BR9803694A (pt) 2000-03-21
HUP9801072A3 (en) 1999-03-29
ES2166577T3 (es) 2002-04-16
HUP9801072A2 (hu) 1999-02-01
PT878467E (pt) 2002-04-29
JP4384277B2 (ja) 2009-12-16
EP0878467B1 (de) 2001-10-31

Similar Documents

Publication Publication Date Title
AR012684A1 (es) Acidos 6- y 7-amino-tetrahidroisoquinolinacarboxilicos sustituidos, procedimiento para su preparacion, su utilizacion en la preparacion de unmedicamento, medicamento que los contienen y procedimiento para su preparacion
ES2509820T3 (es) Derivados de indazol como inhibidores de la cinasa para el tratamiento del cáncer
AR008386A1 (es) DERIVADOS DE BENZIMIDAZOL CON ACTIVIDAD ANTIHISTAMINICA Y COMPOSICIoN FARMACÉUTICA ANTIHISTAMINICA QUE LOS CONTIENE.
AR012675A1 (es) Acidos diaminocarboxilicos sustituidos, compuestos intermediarios, procedimiento para la preparacion de dichos compuestos, medicamentos, uso dedichos compuestos para la preparacion de medicamentos y procedimiento para la preparacion de un medicamento
UY32591A (es) Inhibidores ciclicos de 11beta-hidroxiesteroide deshidrogenasa 1
AR067886A1 (es) Derivados de acido azabifenilaminobenzoico
AR040352A1 (es) Derivados de indolinfenilsulfonamida
AR066509A1 (es) Derivados de tiazol, medicamentos que los contienen, proceso de preparacion y usos como moduladores de beta amiloide.
CO4930264A1 (es) Nuevos derivados de acido piperidin-cetocarboxilico y la obtencion de los mismos
CO6321261A2 (es) Derivados biciclicos heterociclicos o espirobiciclicos heterociclicos enlazados de pirazolo [1,5-a] pirimidinas procedimientos para su preparacion y usos de los mismos
PE20021152A1 (es) Derivados de oxazol como agonistas de receptores activados por proliferacion de peroxisoma
AR091112A1 (es) Benzamidas n-sustituidas como inhibidores de los canales de sodio nav1.7
AR066095A1 (es) Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla
AR088304A1 (es) 5,7-imidazo[1,2-c]pirimidinas sustituidas
CO6300939A2 (es) Compuestos novedosos que son inhibidores de erk referencia a una solicitud relacionada
AR064996A1 (es) Derivados de purina
EA200801494A1 (ru) Производные оксадиазола с активностью crth2 рецептора
DOP2009000106A (es) Compuestos de pirazol y triazol sustituídos como inhibidores de ksp
UY31334A1 (es) 3a,4,5,6,7,7a-hexahidro-3h-benzoimidazol y derivaods de 3a, 4,5,6,,7,7a-hexahidro-3-indol, enantiómeros, diastereoisómeros, sales farmacéuticamente aceptadas, mezclas, composiciones, preparaciones y aplicaciones de las mismas
AR070188A1 (es) Derivados de sulfonamidas sustituidas
ES350204A1 (es) Un procedimiento de preparar 1,4-dihidro-4-(2-trifluorome- tilfenil) piridinas.
UY28715A1 (es) Derivados de diarilmetil piperazina, sus preparaciones y sus usos
DE502005008834D1 (de) Phenylpropandiol-farbstoffvorprodukte
AR077316A2 (es) Compuestos heterociclicos apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6
PE20050293A1 (es) Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos